Full Press Release Details
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology Annual Meeting And The British Pain Society 56th Annual Scientific Meeting 2023.
LXRX
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology Annual Meeting And The British Pain Society 56th Annual Scientific Meeting 2023
Key Takeaway: Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology Annual Meeting And The British Pain Society 56th Annual Scientific Meeting 2023
Price reaction · baseline $2.45 (2023-04-20 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close
+1.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus